Top Page
Opyl Ltd.
(Sydney:OPL)
Opyl Ltd. (OPL) vs. iShares MSCI Australia ETF (EWA)
Opyl Ltd. Business Overview & Revenue Model
Opyl Ltd. Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 397.64K | 617.91K | 902.41K | 767.72K | 620.78K |
| Gross Profit | -1.40M | -1.04M | -620.00K | -465.00K | -276.00K |
| EBITDA | -2.68M | -1.70M | -2.06M | -1.14M | -857.00K |
| Net Income | -3.13M | -1.73M | -2.09M | -1.14M | -926.00K |
Balance Sheet | |||||
| Total Assets | 411.60K | 709.58K | 979.22K | 2.50M | 935.77K |
| Cash, Cash Equivalents and Short-Term Investments | 374.64K | 452.88K | 786.33K | 2.32M | 800.09K |
| Total Debt | 0.00 | 300.00K | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 501.76K | 1.11M | 712.21K | 314.75K | 216.59K |
| Stockholders Equity | -90.16K | -403.59K | 267.01K | 2.19M | 719.18K |
Cash Flow | |||||
| Free Cash Flow | -2.07M | -1.37M | -1.53M | -918.13K | -1.10M |
| Operating Cash Flow | -2.06M | -1.36M | -1.52M | -903.65K | -1.03M |
| Investing Cash Flow | -17.71K | -2.22K | -10.39K | -14.48K | -67.44K |
| Financing Cash Flow | 2.00M | 1.03M | 0.00 | 2.43M | 1.81M |
Opyl Ltd. Technical Analysis
Opyl Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | AU$36.61M | 20.00 | 87.09% | 9.33% | 1.86% | 16.10% | |
70 Outperform | AU$553.82M | 18.32 | 18.39% | 4.46% | 7.80% | 99.87% | |
67 Neutral | $17.78B | 11.60 | 9.11% | 3.88% | 10.92% | -3.96% | |
54 Neutral | AU$205.89M | ― | -37.20% | ― | ― | 32.02% | |
51 Neutral | AU$731.99M | ― | -112.97% | ― | ― | -84.82% | |
40 Underperform | $80.78M | ― | -99.05% | ― | ― | -33.99% | |
35 Underperform | AU$5.65M | ― | ― | -67.78% | 37.66% |
Opyl Ltd. Corporate Events
Opyl Limited has announced a proposed issue of securities, which includes 35,714,286 unlisted options with an exercise price of $0.03 and an expiry of four years from the issue date, as well as 71,428,572 ordinary fully paid shares. The proposed issue date for these securities is May 13, 2025. This move is part of a placement or other type of issue, and it is subject to the approval of the Australian Securities Exchange (ASX) for quotation. This issuance could potentially impact Opyl Limited’s market positioning by increasing its capital base and providing more liquidity, which may be beneficial for stakeholders.
Opyl Ltd. has announced a proposed issue of 8,000,000 unlisted options, exercisable at a price of 0.0315, with an expiry of four years from the issue date. This strategic move is aimed at raising capital to support the company’s ongoing operations and growth initiatives, potentially strengthening its market position in the healthcare technology sector.
Opyl Limited has successfully completed a $1.5 million oversubscribed placement to accelerate the growth of its AI-driven drug discovery platform, Trialkey. The funds will be used to enhance sales, marketing, and infrastructure, reflecting strong investor confidence in the platform’s potential to revolutionize clinical trial design. The placement was supported by key investors, including Director Antanas Guoga, and involved issuing shares at a discount, with further approvals pending for additional shares and options.
Opyl Limited has made significant strides in its core commercial initiatives, including strategic partnerships and revenue-generating models, as evidenced by the early success of its AI Biotech Fund and TrialKey joint venture. The company has engaged with numerous potential clients through major industry events, leading to new partnerships, such as the one with Avion, which integrates Opyl’s TrialKey into clinical trial workflows. These developments highlight Opyl’s growing influence in the biotech industry and its commitment to expanding its market presence globally.
Opyl Limited announced a late lodgement of a ‘Change of Director’s Interest Notice’ for director Antanas Guoga, related to shares and options acquired in December 2024 and March 2025. The delay was due to an administrative oversight, which the company has addressed, asserting that their current compliance practices are adequate and the incident is isolated.
Opyl Limited has issued clarifications and retractions regarding its January 2025 Investor Presentation, following discussions with the ASX. The company emphasized that several statements in the presentation, including potential revenue figures, client savings, sales targets, and asset under management targets, were not intended as financial forecasts. These statements have been fully retracted, and investors are advised not to rely on them as forecasts. Opyl Limited reiterated its commitment to providing forecasts only when reasonable grounds exist, in compliance with ASIC policies.
Opyl Limited reported a significant decline in revenues by 82.7% to $42,146 for the half-year ending December 31, 2024, with a reduced loss of $683,192 compared to the previous period. The company did not declare any dividends, and the report highlights a material uncertainty regarding its going concern, indicating potential challenges in its financial stability.
Opyl Limited has announced a service level agreement with Avion, a leading CRO, to integrate Opyl’s TrialKey platform into clinical trial planning and execution. This partnership underscores Opyl’s growing market validation and demonstrates the industry’s confidence in its data-driven approach to improving trial outcomes. The collaboration aims to optimize trial design and enhance decision-making, with Opyl providing trial feasibility assessments and analytics support. The agreement reaffirms the platform’s value in transforming clinical trials and indicates a positive trajectory for Opyl’s positioning in the industry.